Zevra Therapeutics (ZVRA) Other Accumulated Expenses (2015 - 2026)

Zevra Therapeutics (ZVRA) has 12 years of Other Accumulated Expenses data on file, last reported at $1.4 million in Q1 2026.

• Quarterly Other Accumulated Expenses fell 58.6% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (down 58.6% YoY) and the FY2025 annual result came in at $1.4 million, down 39.73% from the prior year.
• Other Accumulated Expenses climbed to $1.4 million in Q1 2026, from $1.4 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $9.0 million in Q3 2025 to a low of $7000.0 in Q1 2022.
• A 5-year average of $2.3 million and a median of $1.4 million in 2026 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses plunged 98.18% — and 2023, when it surged 4214.29%.
• Tracing ZVRA's Other Accumulated Expenses over 5 years: stood at $629000.0 in 2022, then surged by 301.27% to $2.5 million in 2023, then slipped by 10.46% to $2.3 million in 2024, then sank by 39.73% to $1.4 million in 2025, then grew by 3.38% to $1.4 million in 2026.
• The last three Other Accumulated Expenses figures came in at $1.4 million (Q1 2026), $1.4 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.